Search
                    Minnesota Paid Clinical Trials
A listing of 2107  clinical trials  in Minnesota  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            889 - 900 of 2107
        
                Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Rare Kidney Stone Consortium Patient Registry
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to collect medical information from a large number of patients in many areas of the world with primary hyperoxaluria (PH), Dent disease, Cystinuria and APRT deficiency. This information will create a registry that will help us to compare similarities and differences in patients and their symptoms. The more patients we are able to enter into the registry, the more we will be able to understand the Primary Hyperoxalurias,Dent disease, cystinuria and APRT and learn bett...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 0 years and 100 years
            Trial Updated:
                07/02/2025
            
            Locations: Dent Disease Registry -Mayo Clinic, Rochester, Minnesota         
        
        
            Conditions: Primary Hyperoxaluria, Dent Disease, Cystinuria, APRT Deficiency
        
            
        
    
                
                                    A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
                                
            
            
        Recruiting
                            
            
                The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                07/01/2025
            
            Locations: Vanda Investigational Site, Rochester, Minnesota         
        
        
            Conditions: Obesity
        
            
        
    
                
                                    A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
                                
            
            
        Recruiting
                            
            
                The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 130 years
            Trial Updated:
                07/01/2025
            
            Locations: Research Site, Rochester, Minnesota         
        
        
            Conditions: Metastatic Colorectal Cancer
        
            
        
    
                
                                    ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
                                
            
            
        Recruiting
                            
            
                The primary purpose of this study is to evaluate the safety and tolerability of ION440.             
        
        
    Gender:
                MALE
            Ages:
                Between 2 years and 65 years
            Trial Updated:
                07/01/2025
            
            Locations: Gillette Children's Specialty Healthcare, Saint Paul, Minnesota         
        
        
            Conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
        
            
        
    
                
                                    Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
                                
            
            
        Recruiting
                            
            
                This research study is evaluating the safety and efficacy (performance) of the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens (IOL) in subjects who receive this IOL in both eyes.             
        
        
    Gender:
                ALL
            Ages:
                22 years and above
            Trial Updated:
                07/01/2025
            
            Locations: Site 107, Bloomington, Minnesota         
        
        
            Conditions: Cataract
        
            
        
    
                
                                    Multi-speed Ergonomic Wheelchair
                                
            
            
        Recruiting
                            
            
                Over one million Americans rely on their upper extremities for manual wheelchair propulsion. Shoulder overuse injuries are prevalent among manual wheelchair users and these injuries often result in shoulder pain. Severe shoulder pain can lead some wheelchair users to transition from manual to powered mobility, complicating transportation, and reducing independence in activities of daily living. This project will expand the understanding of a new wheelchair design that allows better positioning o...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/01/2025
            
            Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota         
        
        
            Conditions: Spinal Cord Diseases, Spinal Cord Injuries
        
            
        
    
                
                                    Metastatic Leiomyosarcoma Biomarker Protocol
                                
            
            
        Recruiting
                            
            
                Leiomyosarcoma (LMS) is one of the most prevalent soft tissue sarcomas (STS) and can occur in various sites including soft tissue, uterus and retroperitoneal large vessels. Metastatic disease occurs in approximately 50% of patients diagnosed with leiomyosarcoma and prognosis is poor in setting of metastatic disease. A minority of patients benefit from treatment with chemotherapy and early biomarkers of benefit from treatment are lacking. A biomarker of tumor response and patient survival benefit...  Read More             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                07/01/2025
            
            Locations: Mayo Clinic, Rochester, Minnesota         
        
        
            Conditions: Leiomyosarcoma
        
            
        
    
                
                                    Shear-wave Elastography Compared to Respiratory Function Testing
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the relationship between transdiaphragmatic pressure (Pdi) and diaphragm shear-wave elastography (SWE) during state-of-the-art respiratory muscle testing including volitional efforts (e.g., maximal inspiratory pressure, maximal expiratory pressure, Valsalva maneuver), as well as maximal phrenic nerve stimulation.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/01/2025
            
            Locations: Mayo Clinic in Rochester, Rochester, Minnesota         
        
        
            Conditions: Respiratory Function Loss, Respiratory Complication
        
            
        
    
                
                                    A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
                                
            
            
        Recruiting
                            
            
                This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occu...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 1 year and 30 years
            Trial Updated:
                07/01/2025
            
            Locations: Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota         
        
        
            Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
        
            
        
    
                
                                    A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
                                
            
            
        Recruiting
                            
            
                The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study to find out how genetic variations in GLP1R alter insulin secretion, in the fasting state and when blood sugars levels are elevated.             
        
        
    Gender:
                ALL
            Ages:
                Between 25 years and 65 years
            Trial Updated:
                07/01/2025
            
            Locations: Mayo Clinic in Rochester, Rochester, Minnesota         
        
        
            Conditions: Healthy
        
            
        
    
                
                                    Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
                                
            
            
        Recruiting
                            
            
                This Phase I-II trial studies the safety and efficacy of autologous dendritic cells and a vaccine called Prevnar in treating patients with liver cancer that cannot be removed by surgery after undergoing standard high-dose external beam radiotherapy. Autologous dendritic cells are immune cells generated from the patients' own white blood cells that are grown in a special lab and trained to stimulate the immune system to destroy tumor cells. A pneumonia vaccine called Prevnar may also help stimula...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/01/2025
            
            Locations: Mayo Clinic in Rochester, Rochester, Minnesota         
        
        
            Conditions: Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
        
            
        
    
                
                                    Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is:
Is there a treatment benefit of TARPEYO® 16 mg QD extended use?
Participants will
* take part in this study for about 19 months
* Have urine tests done
* Have blood samples...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/30/2025
            
            Locations: Washington University in St. Louis, Saint Louis Park, Minnesota         
        
        
            Conditions: IgA Nephropathy
        
            
        
    